{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:33:28Z","timestamp":1782826408501,"version":"3.54.5"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2015,8,21]],"date-time":"2015-08-21T00:00:00Z","timestamp":1440115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0135625","type":"journal-article","created":{"date-parts":[[2015,8,21]],"date-time":"2015-08-21T18:01:41Z","timestamp":1440180101000},"page":"e0135625","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis"],"prefix":"10.1371","volume":"10","author":[{"given":"Justin M.","family":"Belcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Coca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag R.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,8,21]]},"reference":[{"key":"ref1","first-page":"2064","article-title":"Acute kidney injury in cirrhosis","volume":"48","author":"G Garcia-Tsao","year":"2008"},{"key":"ref2","first-page":"1693","article-title":"The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis","volume":"31","author":"D Du Chyron","year":"2005"},{"key":"ref3","first-page":"90","article-title":"Causes of renal failure in patients with decompensated cirrhosis and its impact in hospital mortality","volume":"11","author":"GC Carvalho","year":"2010"},{"key":"ref4","first-page":"488","article-title":"Prognostic importance of the cause of renal failure in patients with cirrhosis","volume":"140","author":"M Mart\u00edn-Llah\u00ed","year":"2010"},{"issue":"12","key":"ref5","first-page":"1550","article-title":"Acute kidney injury in patients with cirrhosis: perils and promise","volume":"11","author":"JM Belcher","year":"2013"},{"key":"ref6","first-page":"968","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Ascites Club","volume":"62","author":"P Angeli","year":"2015"},{"key":"ref7","first-page":"941","article-title":"Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, randomized study","volume":"36","author":"R Ortega","year":"2002"},{"key":"ref8","first-page":"1352","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: A randomized study","volume":"134","author":"M Mart\u00edn-Llah\u00ed","year":"2008"},{"key":"ref9","first-page":"1187","article-title":"Noradrenaline vs terlipressin in the treatment of Type 2 Hepatorenal Syndrome: a randomized pilot study","volume":"33","author":"S Ghosh","year":"2013"},{"issue":"5","key":"ref10","first-page":"539","article-title":"Impact of etiology of acute kidney injury on outcomes following liver transplantation: Acute tubular necrosis versus hepatorenal syndrome","volume":"18","author":"MK Nadim","year":"2012"},{"issue":"11","key":"ref11","first-page":"1328","article-title":"Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1","volume":"17","author":"TD Boyer","year":"2011"},{"issue":"2","key":"ref12","first-page":"315","article-title":"Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics","volume":"55","author":"TD Boyer","year":"2011"},{"key":"ref13","unstructured":"Institute of Medicine. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. 2010."},{"issue":"6","key":"ref14","first-page":"1241","article-title":"Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practices","volume":"55","author":"F Salerno","year":"2011"},{"key":"ref15","first-page":"78","article-title":"Terlipressin and gelafundin: safe therapy of hepatorenal syndrome","volume":"9","author":"F Saner","year":"2004"},{"key":"ref16","first-page":"153","article-title":"Effect of terlipressin (glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicenter pilot study","volume":"14","author":"C Halimi","year":"2002"},{"issue":"Suppl 2","key":"ref17","first-page":"303","article-title":"Terlipressin and albumin combination treatment in hepatorenal syndrome","volume":"50","author":"A Danalioglu","year":"2003"},{"issue":"3","key":"ref18","first-page":"313","article-title":"The efficacy and safety of terlipressin and albumin in patients with Type 1 Hepatorenal Syndrome: a multicenter, open label, exploratory study","volume":"47","author":"Y Narahara","year":"2012"},{"issue":"4","key":"ref19","first-page":"923","article-title":"Terlipressin in patients with cirrhosis and Type 1 Hepatorenal Syndrome: a retrospective multicenter study","volume":"122","author":"R Moreau","year":"2002"},{"issue":"1","key":"ref20","first-page":"21","article-title":"Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study","volume":"47","author":"V Von Kalckreuth","year":"2009"},{"issue":"3","key":"ref21","first-page":"742","article-title":"Octreotide\/Midodrine therapy significantly improves renal function and 30-day survival in patients with Type 1 Hepatorenal Syndrome","volume":"52","author":"E Esrailian","year":"2007"},{"issue":"9","key":"ref22","first-page":"1813","article-title":"Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study","volume":"20","author":"TH Kiser","year":"2005"},{"issue":"2","key":"ref23","first-page":"471","article-title":"Targeting an early and substantial increase in mean arterial pressure is critical in the management of Type 1 Hepatorenal Syndrome: a combined retrospective and pilot study","volume":"59","author":"G Maddukuri","year":"2014"},{"key":"ref24","first-page":"43","article-title":"Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome","volume":"33","author":"J Uriz","year":"2000"},{"key":"ref25","first-page":"374","article-title":"Effects of noradrenalin and albumin in patients with Type 1 Hepatorenal Syndrome: A pilot study","volume":"36","author":"C Duvoux","year":"2002"},{"key":"ref26","first-page":"1363","article-title":"Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2","volume":"14","author":"C Alessandria","year":"2002"},{"key":"ref27","first-page":"55","article-title":"Midodrine, octreotide, albumin and TIPS in selected patients with cirrhosis and Type 1 Hepatorenal Syndrome","volume":"40","author":"F Wong","year":"2004"},{"key":"ref28","first-page":"219","article-title":"Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and Type 1 Hepatorenal Syndrome","volume":"51","author":"A Nazar","year":"2010"},{"issue":"7","key":"ref29","first-page":"680","article-title":"Combination treatment with octreotide, midodrine, and albumin improves survival in patients with Type 1 and Type 2Hepatorenal Syndrome","volume":"43","author":"C Skagen","year":"2009"},{"key":"ref30","first-page":"882","article-title":"Clinical course, predictive factors and prognosis in patients with cirrhosis and Type 1 Hepatorenal Syndrome treated with terlipressin: A retrospective analysis","volume":"17","author":"I Colle","year":"2002"},{"key":"ref31","first-page":"1690","article-title":"Reversal of Type 1 Hepatorenal Syndrome with the administration of midodrine and octreotide","volume":"29","author":"P Angelli","year":"1999"},{"issue":"4","key":"ref32","first-page":"565","article-title":"Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome","volume":"29","author":"A Hadenque","year":"1998"},{"key":"ref33","first-page":"238","article-title":"Octreotide in hepatorenal syndrome: A randomized, double-blind, placebo-controlled, crossover study","volume":"38","author":"G Pomier-Layrargues","year":"2003"},{"key":"ref34","first-page":"15","article-title":"Long-term terlipressin administration improves renal function in cirrhotic patients with Type 1 Hepatorenal Syndrome: a pilot study","volume":"64","author":"JP Mulkay","year":"2001"},{"key":"ref35","first-page":"35","article-title":"Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion","volume":"27","author":"M Guevara","year":"1998"},{"key":"ref36","first-page":"1689","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of Type 1 Hepatorenal Syndrome and predictors of response","volume":"108","author":"P Sharma","year":"2008"},{"key":"ref37","first-page":"152","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial","volume":"18","author":"P Solanki","year":"2003"},{"issue":"6","key":"ref38","first-page":"916","article-title":"Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome","volume":"25","author":"J Sal\u00f3","year":"1996"},{"key":"ref39","first-page":"1360","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for Type 1 Hepatorenal Syndrome","volume":"134","author":"AJ Sanyal","year":"2008"},{"key":"ref40","first-page":"499","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblended study","volume":"47","author":"C Alessandria","year":"2007"},{"key":"ref41","first-page":"1293","article-title":"Noradrenaline vs terlipressin in the treatment of hepatorenal syndrome: A randomized study","volume":"56","author":"V Singh","year":"2012"},{"key":"ref42","first-page":"830","article-title":"Terlipressin and albumin in patients with cirrhosis and Type 1 Hepatorenal Syndrome","volume":"53","author":"S Neri","year":"2008"},{"key":"ref43"},{"issue":"3","key":"ref44","first-page":"1014","article-title":"Criteria for the validation of surrogate endpoints in randomized experiments","volume":"54","author":"M Buyse","year":"1998"},{"issue":"3","key":"ref45","first-page":"437","article-title":"Meta-analysis: methods, strengths, and weaknesses","volume":"14","author":"M Buyse","year":"2000"},{"issue":"20","key":"ref46","first-page":"3023","article-title":"Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes","volume":"20","author":"G Molenberghs","year":"2001"},{"key":"ref47","first-page":"d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"JA Sterne","year":"2011"},{"issue":"21","key":"ref48","first-page":"2191","article-title":"Kidney function after off-pump or on-pump coronary artery bypass graft surgery: a randomized clinical trial","volume":"311","author":"AX Garg","year":"2014"},{"issue":"1","key":"ref49","first-page":"175","article-title":"Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis","volume":"43","author":"M Dobre","year":"2011"},{"issue":"3","key":"ref50","first-page":"133","article-title":"Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials","volume":"32","author":"F Fabrizi","year":"2009"},{"key":"ref51","first-page":"CD005162","article-title":"Terlipressin for hepatorenal syndrome","volume":"9","author":"LL Gluud","year":"2012"},{"issue":"23","key":"ref52","first-page":"2448","article-title":"Television viewing and risk of Type 2 diabetes, cardiovascular disease, and all-cause mortality","volume":"305","author":"A Gr\u00f8ntved","year":"2011"},{"key":"ref53","first-page":"197","article-title":"Efficacy and safety of atomoxetine for attention-deficit\/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis","volume":"194","author":"JYW Cheng","year":"2007"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0135625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T10:12:27Z","timestamp":1540030347000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0135625"}},"subtitle":[],"editor":[{"given":"Han-Chieh","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,8,21]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0135625","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,21]]}}}